Larry Kilby, MD
Adult Medicine · Winston Salem, NCNPI 1710174636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $979 and has fallen 80.1% since, to $195 in 2025. Among adult medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$576
- Pfizer$440
- AbbVie$373
- Lilly USA, LLC$284
- GSK$234
- Boehringer Ingelheim$232
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $576 |
| Pfizer | 24 | $440 |
| AbbVie | 19 | $373 |
| Lilly USA, LLC | 19 | $284 |
| GSK | 5 | $234 |
| Boehringer Ingelheim | 9 | $232 |
| Amgen(2 entities) | 10 | $221 |
| AstraZeneca | 12 | $190 |
| Novartis | 9 | $156 |
| Astellas Pharma US Inc | 10 | $145 |
| Sunovion Pharmaceuticals Inc. | 8 | $120 |
| Merck | 7 | $107 |
| Abbott | 4 | $88 |
| Amarin Pharma, Inc. | 5 | $88 |
| Xeris Pharmaceuticals, Inc. | 5 | $73 |
| Esperion Therapeutics, Inc. | 1 | $65 |
| Alkermes, Inc. | 1 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Dexcom, Inc. | 2 | $56 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Baxter Healthcare | 1 | $25 |
| Genentech USA, Inc. | 1 | $22 |
| RGH Enterprises LLC | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Tris Pharma Inc | 1 | $14 |
| Medicure Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$105
How this compares
$3,939 in reported general payments places this provider in the 95th percentile of 25 adult medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 13 | $14,645 |
| OzempicSemaglutide | 11 | $10,280 |
| Pitavastatin Calcium | 19 | $4,025 |
| EdarbiAzilsartan Medoxomil | 12 | $2,881 |
| Levothyroxine Sodium | 46 | $486 |
| Rosuvastatin Calcium | 38 | $434 |
| Losartan Potassium | 42 | $329 |
| Amlodipine Besylate | 45 | $327 |
| Celecoxib | 25 | $324 |
| Gabapentin | 12 | $269 |
| Metoprolol Succinate | 18 | $255 |
| Omeprazole | 16 | $242 |
| Simvastatin | 15 | $213 |
| Olmesartan Medoxomil | 16 | $173 |
| Furosemide | 33 | $157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $232 | $14,64513 claims |
| Novo NordiskOzempic | $576 | $10,28011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 25 adult medicine providers in North Carolina.
Other adult medicine in Winston Salem
- Monika Gonzalez KrollWinston Salem$129
- Antonia TettamantiWinston Salem$12
- Mark BlizzardGoldsboro$6K
- Kathryn LongCharlotte$1K
- John CaplingerSylva$1K
- Christele MartinReidsville$992
- Mary-Emma BeresElkin$676
- Mary Rockers TyniDurham$545
- Debra OrrRaleigh$542
- Eduvigis CarreraPinehurst$415
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.